SCHEMBL4808083

SCHEMBL4808083

CN(C1CCC(O)CC1)S(=O)(=O)c1ccc(Br)cc1

nearest known ligand 0.50

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.50
KDM4E B2RXH2 2/20 0.50
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
HTR2A P28223 13/20 0.49
HTR2C P28335 13/20 0.49
L3MBTL1 Q9Y468 4/20 0.48
LMNA P02545 3/20 0.47
GAA P10253 3/20 0.47
HTT P42858 2/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
MAPT P10636 1/20 0.44
ALOX15 P16050 1/20 0.44
HSD17B10 Q99714 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4808088 1.00 ALDH1A1 (0.50) ALDH1A1KDM4EMEN1KMT2AHTR2A
SCHEMBL4799950 0.82 HTR2A (0.68) ALDH1A1KDM4EMEN1KMT2AHTR2A
SCHEMBL4799957 0.82 HTR2A (0.68) ALDH1A1KDM4EMEN1KMT2AHTR2A
SCHEMBL14720872 0.81 ALDH1A1 (0.50) ALDH1A1KDM4EMEN1KMT2AHTR2A
SCHEMBL6034142 0.80 HTR2A (0.76) ALDH1A1HTR2AHTR2CL3MBTL1GAA
SCHEMBL4804051 0.76 HTR2A (0.44) ALDH1A1KDM4EHTR2AHTR2CL3MBTL1
SCHEMBL4804061 0.76 HTR2A (0.44) ALDH1A1KDM4EHTR2AHTR2CL3MBTL1
SCHEMBL27895777 0.75 ALDH1A1 (0.57) ALDH1A1KDM4EMEN1KMT2AHTR2A
SCHEMBL6034181 0.75 HTR2A (0.63) ALDH1A1HTR2AHTR2CL3MBTL1GAA
SCHEMBL2505847 0.74 ALDH1A1 (0.83) ALDH1A1KDM4EMEN1KMT2AHTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-100455566-C Novel derivatives of aminocyclohexane HOFFMANN LA ROCHE (CH) 2009-01-28 CN disclosed
EP-1311475-B1 AMINOCYCLOHEXANE DERIVATIVES HOFFMANN LA ROCHE (CH) 2008-08-06 EP disclosed
US-7335687-B2 2,3-Oxidosqualene-lanosterol cyclase inhibitors HOFFMANN-LA ROCHE INC. (US) 2008-02-26 US disclosed
US-20050176766-A1 2,3-Oxidosqualene-lanosterol cyclase inhibitors ACKERMANN JEAN (CH) 2005-08-11 US disclosed
US-6858651-B2 2,3-oxidosqualene-lanosterol cyclase inhibitors HOFFMANN-LA ROCHE INC. (US) 2005-02-22 US disclosed
CN-1468214-A Novel derivatives of aminocyclohexane - 2004-01-14 CN disclosed
EP-1311475-A1 NOVEL AMINOCYCLOHEXANE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2003-05-21 EP disclosed
US-20020045777-A1 2,3-oxidosqualene-lanosterol cyclase inhibitors F.HOFFMANN-LA ROCHE AG (CH) 2002-04-18 US disclosed
WO-2002014267-A1 NOVEL AMINOCYCLOHEXANE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2002-02-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050176766-A1 2,3-Oxidosqualene-lanosterol cyclase inhibitors CYP51A1, LSS, CYP46A1 ALDH1A1 2260/4885KDM4E 4198/4885MEN1 429/4885
US-20020045777-A1 2,3-oxidosqualene-lanosterol cyclase inhibitors CYP51A1, LSS, CYP46A1 ALDH1A1 2260/4885KDM4E 4198/4885MEN1 429/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.